TOT BIOPHARM International Company Limited

SEHK:1875 주식 보고서

시가총액: HK$1.5b

TOT BIOPHARM International 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jun Liu

최고 경영자

CN¥7.5m

총 보상

CEO 급여 비율49.5%
CEO 임기5.7yrs
CEO 소유권n/a
경영진 평균 재임 기간4.2yrs
이사회 평균 재임 기간5.7yrs

최근 관리 업데이트

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Recent updates

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

May 21
The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Mar 18
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Dec 28
There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

Nov 23
Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

May 18
We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Jul 27
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Mar 26
An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Feb 03
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

CEO 보상 분석

Jun Liu 의 보수는 TOT BIOPHARM International 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

CN¥9m

Mar 31 2024n/an/a

-CN¥14m

Dec 31 2023CN¥8mCN¥4m

-CN¥38m

Sep 30 2023n/an/a

-CN¥44m

Jun 30 2023n/an/a

-CN¥49m

Mar 31 2023n/an/a

-CN¥50m

Dec 31 2022CN¥5mCN¥3m

-CN¥50m

Sep 30 2022n/an/a

-CN¥106m

Jun 30 2022n/an/a

-CN¥162m

Mar 31 2022n/an/a

-CN¥212m

Dec 31 2021CN¥3mCN¥2m

-CN¥261m

보상 대 시장: Jun 의 총 보상 ($USD 1.04M )은 Hong Kong 시장( $USD 347.84K ).

보상과 수익: Jun 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Jun Liu (56 yo)

5.7yrs

테뉴어

CN¥7,528,000

보상

Dr. Jun Liu serves as Chief Executive Officer at TOT BIOPHARM International Company Limited since October 15, 2020 and serves as its Executive Director since October 26, 2018. Dr. Liu serves as Chief Scien...


리더십 팀

이름위치테뉴어보상소유권
Jun Liu
CEO, Chief Scientific Officer & Executive Director5.7yrsCN¥7.53m데이터 없음
Ben Xiao
Executive Finance Director2.8yrs데이터 없음데이터 없음
Wing Yat Lui
Joint Company Secretary5.6yrs데이터 없음데이터 없음
Yifan Chen
Joint Company Secretary2.8yrs데이터 없음데이터 없음

4.2yrs

평균 재임 기간

43yo

평균 연령

경험이 풍부한 관리: 1875 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Jun Liu
CEO, Chief Scientific Officer & Executive Director6.1yrsCN¥7.53m데이터 없음
Shan Fu
Chairman of the Board8.8yrs데이터 없음데이터 없음
Hong-Jen Chang
Independent Non-Executive Director5.7yrsCN¥282.00k데이터 없음
Chun-Ying Yeh-Huang
Non-Executive Vice Chairman of the Board8.8yrsCN¥600.00k0.71%
HK$ 10.3m
Lan Hu
Independent Non-Executive Director5.7yrsCN¥282.00k데이터 없음
Weidong Liu
Non-Executive Director1.3yrs데이터 없음데이터 없음
De Qian Wang
Independent Non-Executive Director2.7yrsCN¥282.00k데이터 없음

5.7yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 1875 의 이사회경험(평균 재직 기간 5.7 년)으로 간주됩니다.